MannKind to Present at Upcoming Investor Conferences
MNKDDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind’s Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
MNKDMannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MNKDDANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MNKDMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin At American Diabetes Association's 85th Scientific Sessions
MNKDMannKind Q1 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $78.35M Beat $76.13M Estimate
MNKDMannKind's Earnings Outlook
MNKDMizuho Initiates Coverage On MannKind with Outperform Rating, Announces Price Target of $12
MNKDMannKind to Present New Inhaled Insulin Data at Global Diabetes Conference in Amsterdam
MNKDWells Fargo Initiates Coverage On MannKind with Overweight Rating, Announces Price Target of $9
MNKDRBC Capital Upgrades MannKind to Outperform, Raises Price Target to $10
MNKDMannKind Completes Phase 1 Trial of Inhaled Therapy for Lung Disease, Results Show Nintedanib DPI Safe and Tolerable
MNKDMannKind Earnings Preview
MNKDMannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that MannKind will report an earnings per share (EPS) of $-0.10.
